GSK's oncology sales increased 98% in 2024, and reflects strong demand and potentially new launches or indications for cancer therapies.

GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...

GSK's drive to resurrect its multiple myeloma ... The new data from the study shows that Blenrep (belantamab mafodotin) was more effective at extending OS than Genmab and Johnson & Johnson's ...

PLYMOUTH, Mass., January 13, 2025--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...

After hours: February 3 at 6:25:46 p.m. EST ...

24 Jul, 2018 11 Sep, 2018 1:1 For every 1 share held; Holder will receive 1 bonus shares. 28 Sep, 1994 02 Jan, 1995 1:1 For every 1 share held; Holder will receive 1 bonus shares. 23 Jun, 1980-1:3 ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.